Innovative Treatment Adoption Flyte by Pelvital offers a groundbreaking, FDA-cleared in-home treatment for urinary incontinence, making it highly appealing to women seeking effective, non-invasive solutions and healthcare providers looking for alternative therapies to surgical interventions.

Growing Funding Momentum Recent seed and seed-plus funding rounds totaling over $10 million, including investments from Boomerang Ventures and Pelvital’s own financial rounds, indicate strong investor confidence and growing resources available for sales expansion and product development.

Product Innovation & Expansion The launch of a next-generation Flyte System reflects ongoing product enhancements that can be leveraged to upsell to existing customers and attract new clinics and hospitals seeking the latest in pelvic health technology.

Market Expansion Potential Pelvital's focus on accessible, conservative pelvic health treatments aligns well with current healthcare trends toward minimally invasive solutions, creating opportunities to partner with clinics, physiotherapists, and women's health specialists pursuing innovative patient care options.

Targeted Customer Base With a dedicated focus on women's pelvic health and a dedicated website, Flyte can expand its reach through targeted marketing and education campaigns aimed at both clinicians and women suffering from urinary incontinence, fostering increased adoption and brand loyalty.